Do analysts recommend SLSN or NUS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nu Skin Enterprises 2 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer SLSN or NAGE?

Niagen Bioscience has a consensus price target of $10.33, indicating a potential upside of 284.14%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Solesence. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Niagen Bioscience 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00

Do analysts rate SLSN or MED?

Medifast has a consensus target price of $12.00, indicating a potential upside of 3.36%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than Solesence. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medifast 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SLSN or MED more profitable?

Solesence has a net margin of -3.40% compared to Medifast's net margin of -8.08%. Medifast's return on equity of -6.69% beat Solesence's return on equity. Company Net Margins Return on Equity Return on Assets Solesence -3.40% -11.58% -3.79% Medifast -8.08% -6.69% -5.25%

Do analysts prefer WALD or SLSN?

Waldencast currently has a consensus price target of $2.33, indicating a potential upside of 168.51%. Given Waldencast's stronger consensus rating and higher probable upside, analysts clearly believe Waldencast is more favorable than Solesence. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Waldencast 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Solesence 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, WALD or SLSN?

Solesence has lower revenue, but higher earnings than Waldencast. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Waldencast $272.07M 0.41 -$229.75M N/A N/A Solesence $62.06M 1.16 $1.79M -$0.03 N/A

Solesence (SLSN) Competitors

$1.02 +0.18 (+21.98%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.03 +0.01 (+0.78%)

As of 10/9/2026 07:56 PM Eastern

Compare

SLSN vs. NUS, NATR, NAGE, MED, and WALD

Should you buy Solesence stock or one of its competitors? Solesence's main competitors and comparable companies include Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Niagen Bioscience (NAGE), Medifast (MED), and Waldencast (WALD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Solesence compare to Nu Skin Enterprises?

Solesence (NASDAQ:SLSN) and Nu Skin Enterprises (NYSE:NUS) are both small-cap consumer staples companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Solesence has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nu Skin Enterprises	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nu Skin Enterprises has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than Nu Skin Enterprises, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.16	$1.79M	-$0.03	N/A
Nu Skin Enterprises	$1.49B	0.16	$160.20M	-$4.47	N/A

In the previous week, Solesence had 1 more articles in the media than Nu Skin Enterprises. MarketBeat recorded 1 mentions for Solesence and 0 mentions for Nu Skin Enterprises. Nu Skin Enterprises' average media sentiment score of 0.25 beat Solesence's score of 0.00 indicating that Nu Skin Enterprises is being referred to more favorably in the news media.

Company	Overall Sentiment
Solesence	Neutral
Nu Skin Enterprises	Neutral

70.2% of Solesence shares are held by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are held by institutional investors. 4.8% of Solesence shares are held by company insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Solesence has a net margin of -3.40% compared to Nu Skin Enterprises' net margin of -15.73%. Nu Skin Enterprises' return on equity of 6.58% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Nu Skin Enterprises	-15.73%	6.58%	3.63%

Summary

Nu Skin Enterprises beats Solesence on 7 of the 13 factors compared between the two stocks.

How does Solesence compare to Nature's Sunshine Products?

Nature's Sunshine Products (NASDAQ:NATR) and Solesence (NASDAQ:SLSN) are both small-cap consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

79.4% of Nature's Sunshine Products shares are held by institutional investors. Comparatively, 70.2% of Solesence shares are held by institutional investors. 3.1% of Nature's Sunshine Products shares are held by insiders. Comparatively, 4.8% of Solesence shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Nature's Sunshine Products had 2 more articles in the media than Solesence. MarketBeat recorded 3 mentions for Nature's Sunshine Products and 1 mentions for Solesence. Nature's Sunshine Products' average media sentiment score of 1.56 beat Solesence's score of 0.00 indicating that Nature's Sunshine Products is being referred to more favorably in the media.

Company	Overall Sentiment
Nature's Sunshine Products	Very Positive
Solesence	Neutral

Nature's Sunshine Products currently has a consensus price target of $30.50, indicating a potential upside of 141.30%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, research analysts plainly believe Nature's Sunshine Products is more favorable than Solesence.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nature's Sunshine Products	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nature's Sunshine Products has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Solesence has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market.

Nature's Sunshine Products has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nature's Sunshine Products	$480.14M	0.46	$19.52M	$1.01	12.51
Solesence	$62.06M	1.16	$1.79M	-$0.03	N/A

Nature's Sunshine Products has a net margin of 3.68% compared to Solesence's net margin of -3.40%. Nature's Sunshine Products' return on equity of 12.88% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nature's Sunshine Products	3.68%	12.88%	8.17%
Solesence	-3.40%	-11.58%	-3.79%

Summary

Nature's Sunshine Products beats Solesence on 13 of the 16 factors compared between the two stocks.

How does Solesence compare to Niagen Bioscience?

Solesence (NASDAQ:SLSN) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Niagen Bioscience had 4 more articles in the media than Solesence. MarketBeat recorded 5 mentions for Niagen Bioscience and 1 mentions for Solesence. Niagen Bioscience's average media sentiment score of 0.63 beat Solesence's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Solesence	Neutral
Niagen Bioscience	Positive

Niagen Bioscience has higher revenue and earnings than Solesence. Solesence is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.16	$1.79M	-$0.03	N/A
Niagen Bioscience	$129.42M	1.66	$17.38M	$0.18	14.94

Niagen Bioscience has a net margin of 12.39% compared to Solesence's net margin of -3.40%. Niagen Bioscience's return on equity of 17.95% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Niagen Bioscience	12.39%	17.95%	13.17%

Niagen Bioscience has a consensus price target of $10.33, indicating a potential upside of 284.14%. Given Niagen Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Niagen Bioscience is more favorable than Solesence.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Solesence has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

70.2% of Solesence shares are owned by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are owned by institutional investors. 4.8% of Solesence shares are owned by insiders. Comparatively, 10.0% of Niagen Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Niagen Bioscience beats Solesence on 16 of the 17 factors compared between the two stocks.

How does Solesence compare to Medifast?

Solesence (NASDAQ:SLSN) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Solesence has higher earnings, but lower revenue than Medifast. Solesence is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solesence	$62.06M	1.16	$1.79M	-$0.03	N/A
Medifast	$385.79M	0.34	-$18.67M	-$2.33	N/A

Solesence has a net margin of -3.40% compared to Medifast's net margin of -8.08%. Medifast's return on equity of -6.69% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solesence	-3.40%	-11.58%	-3.79%
Medifast	-8.08%	-6.69%	-5.25%

In the previous week, Medifast had 5 more articles in the media than Solesence. MarketBeat recorded 6 mentions for Medifast and 1 mentions for Solesence. Medifast's average media sentiment score of 0.79 beat Solesence's score of 0.00 indicating that Medifast is being referred to more favorably in the news media.

Company	Overall Sentiment
Solesence	Neutral
Medifast	Positive

70.2% of Solesence shares are held by institutional investors. Comparatively, 95.5% of Medifast shares are held by institutional investors. 4.8% of Solesence shares are held by insiders. Comparatively, 3.7% of Medifast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Solesence has a beta of 1.37, meaning that its stock price is 37% more volatile than the broader market. Comparatively, Medifast has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Medifast has a consensus target price of $12.00, indicating a potential upside of 3.36%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than Solesence.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medifast	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Medifast beats Solesence on 8 of the 15 factors compared between the two stocks.

How does Solesence compare to Waldencast?

Waldencast (NASDAQ:WALD) and Solesence (NASDAQ:SLSN) are both small-cap consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Waldencast has a net margin of 0.00% compared to Solesence's net margin of -3.40%. Waldencast's return on equity of 0.00% beat Solesence's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Waldencast	N/A	N/A	N/A
Solesence	-3.40%	-11.58%	-3.79%

Solesence has lower revenue, but higher earnings than Waldencast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Waldencast	$272.07M	0.41	-$229.75M	N/A	N/A
Solesence	$62.06M	1.16	$1.79M	-$0.03	N/A

In the previous week, Waldencast and Waldencast both had 1 articles in the media. Solesence's average media sentiment score of 0.00 beat Waldencast's score of -0.26 indicating that Solesence is being referred to more favorably in the news media.

Company	Overall Sentiment
Waldencast	Neutral
Solesence	Neutral

42.0% of Waldencast shares are owned by institutional investors. Comparatively, 70.2% of Solesence shares are owned by institutional investors. 4.8% of Solesence shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Waldencast has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market. Comparatively, Solesence has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Waldencast currently has a consensus price target of $2.33, indicating a potential upside of 168.51%. Given Waldencast's stronger consensus rating and higher probable upside, analysts clearly believe Waldencast is more favorable than Solesence.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Waldencast	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Solesence	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Waldencast beats Solesence on 7 of the 13 factors compared between the two stocks.

Get Solesence News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLSN vs. The Competition

Export

Metric	Solesence	Personal Care Products Industry	Consumer Staples Sector	NASDAQ Exchange
Market Cap	$59.08M	$23.02B	$15.86B	$13.21B
Dividend Yield	N/A	5.53%	3.31%	16.37%
P/E Ratio	-34.00	21.85	13.88	26.16
Price / Sales	1.16	12.82	265,659.24	107.50
Price / Cash	21.95	26.14	57.04	53.09
Price / Book	4.08	2.89	4.34	6.33
Net Income	$1.79M	$1.13B	$844.17M	$382.15M
7 Day Performance	24.39%	1.21%	0.85%	-1.40%
1 Month Performance	22.88%	-4.23%	-2.53%	-3.47%
1 Year Performance	-71.35%	-19.53%	9.74%	1.18%

Solesence Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLSN Solesence	0.22 of 5 stars	$1.02 +22.0%	N/A	-72.0%	$59.08M	$62.06M	N/A	115	Positive News High Trading Volume
NUS Nu Skin Enterprises	1.6219 of 5 stars	$4.61 +1.2%	N/A	-56.8%	$224.40M	$1.38B	N/A	2,800	News Coverage
NATR Nature's Sunshine Products	3.9939 of 5 stars	$12.45 -1.1%	$30.50 +145.0%	-14.8%	$221.53M	$480.14M	12.33	806	Positive News
NAGE Niagen Bioscience	3.38 of 5 stars	$2.79 +4.1%	$10.33 +270.4%	-64.4%	$213.45M	$129.42M	15.50	117	News Coverage High Trading Volume
MED Medifast	2.327 of 5 stars	$11.73 +2.6%	$12.00 +2.3%	-17.1%	$127.79M	$385.79M	N/A	380	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLSN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Solesence (SLSN) Competitors

SLSN vs. NUS, NATR, NAGE, MED, and WALD

How does Solesence compare to Nu Skin Enterprises?

Summary

How does Solesence compare to Nature's Sunshine Products?

Summary

How does Solesence compare to Niagen Bioscience?

Summary

How does Solesence compare to Medifast?

Summary

How does Solesence compare to Waldencast?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLSN vs. The Competition

Solesence Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Solesence (SLSN) Competitors

SLSN vs. NUS, NATR, NAGE, MED, and WALD

How does Solesence compare to Nu Skin Enterprises?

Which has more volatility and risk, SLSN or NUS?

Do analysts recommend SLSN or NUS?

Which has preferable earnings & valuation, SLSN or NUS?

Does the media refer more to SLSN or NUS?

Do insiders & institutionals have more ownership in SLSN or NUS?

Is SLSN or NUS more profitable?

Summary

How does Solesence compare to Nature's Sunshine Products?

Do insiders and institutionals believe in NATR or SLSN?

Does the media favor NATR or SLSN?

Do analysts recommend NATR or SLSN?

Which has more volatility & risk, NATR or SLSN?

Which has preferable earnings & valuation, NATR or SLSN?

Is NATR or SLSN more profitable?

Summary

How does Solesence compare to Niagen Bioscience?

Does the media prefer SLSN or NAGE?

Which has preferable earnings and valuation, SLSN or NAGE?

Is SLSN or NAGE more profitable?

Do analysts prefer SLSN or NAGE?

Which has more risk & volatility, SLSN or NAGE?

Do institutionals and insiders believe in SLSN or NAGE?

Summary

How does Solesence compare to Medifast?

Which has stronger earnings & valuation, SLSN or MED?

Is SLSN or MED more profitable?

Does the media refer more to SLSN or MED?

Do institutionals & insiders hold more shares of SLSN or MED?

Which has more risk & volatility, SLSN or MED?

Do analysts rate SLSN or MED?

Summary

How does Solesence compare to Waldencast?

Is WALD or SLSN more profitable?

Which has better earnings & valuation, WALD or SLSN?

Does the media prefer WALD or SLSN?

Do institutionals and insiders believe in WALD or SLSN?

Which has more volatility and risk, WALD or SLSN?

Do analysts prefer WALD or SLSN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLSN vs. The Competition

Solesence Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools